ReWalk Robotics Announces Warrant Exercise Generating $ 10.8 Million In Cash Proceeds

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., June 05 2019 (GLOBE NEWSWIRE) – ReWalk Robotics Ltd. (RWLK) ("ReWalk" or the "Company"), today announced the agreement entered into by several qualified investors on its common share purchase warrants to exercise and purchase 1,446,665 common shares at a price $ 7.50 per share. & Nbsp; Ordinary shares issued during the fiscal year are registered in accordance with the Corporation's registration statement on Form S-1, as amended (File No. 333-227852), relating to such Common Shares, registration statement that has been declared effective by the Securities and Exchange Commission (SEC) on November 15, 2018 (the "Registration Statement"). & Nbsp; Gross proceeds from the exercise of the warrants are expected to be approximately $ 10.8 million, before deducting the expenses of the distribution agent fee and estimated issuance costs.
"data-reactid =" 11 "> YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., June 5, 2019 (GLOBE NEWSWIRE) – ReWalk Robotics Ltd. (RWLK) (" ReWalk "or" the company ") announced today the agreement of several qualified investors on its common share purchase warrants to exercise and purchase 1,446,665 of its common shares at a price of $ 7.50 per share, and the common shares issued upon exercise are recorded in accordance with the Corporation's registration statement on Form S-1, as amended (file number 333-227852), relating to these Common Shares, registration statement that has been declared effective by the Securities and Exchange Commission (SEC ) November 15, 2018 (the "Registration Statement") .The gross proceeds of the exercise approximately $ 10.8 million of warrants, before deduction of agent fees and fees investment funds.

In consideration of the immediate exercise of the warrants and a private placement in accordance with Section 4 (a) (2) of the Securities Act of 1933, as amended, the holders who exercise will receive unregistered warrants. The common share purchase warrant may be exercised, in aggregate, out of a maximum of 1,446,665 common shares at a fiscal year-end price of $ 7.50 and will have a fiscal year-end equal to five years.

H.C. Wainwright & Co. acts as the sole placement agent for the exercise of the mandates.

ReWalk intends to use the net proceeds of the offering to (i) cover the selling, marketing and reimbursement costs associated with the ReStore device market development activities and expand coverage the third party payer for the ReWalk Personal device, as well as (ii) research and development costs related to the development of the Company's lightweight exotic combination technology for various lower limb disabilities, including strokes and other indications affecting the ability to walk.

The new warrants described above were offered by way of a private placement pursuant to an applicable exemption from the listing requirements of the Securities Act of 1933, as amended (the "Act"), and, with the shares may be issued upon exercise, registered under the law, and may not be offered or sold in the United States without registration with the SEC or applicable exemption from such registration requirements. The securities were offered only to qualified investors. The Company has agreed to use its best efforts to file with the SEC one or more registration statements covering the resale of the common shares of the issuer that may be issued upon the exercise of the warrants. .

This press release does not constitute an offer to sell or a solicitation of an offer to purchase, and no sale of such securities will take place in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "About & nbsp; ReWalk Robotics Ltd."data-reactid =" 17 ">About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets portable robotic exoskeletons for people with lower extremity disability as a result of spinal cord injury or stroke. ReWalk's mission is to fundamentally change the quality of life for people with lower limb disability through the creation and development of advanced robotic technologies. Founded in 2001, ReWalk is headquartered in the United States, Israel and Germany. For more information on ReWalk systems, please visit www.rewalk.com.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.

ReStore® is a registered trademark of ReWalk Robotics Ltd in Europe.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Forward-looking statements"data-reactid =" 21 ">Forward-looking statements

In addition to the historical information, this press release contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, sections 27A of the US Securities Act of 1933 and 21E of the US Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the future performance of ReWalk and, in some cases, be identified by words such as "anticipate", "assume", "believe", "continue", "could", "estimate", "expect". , "Intention", "may", "plan", "potential", "predict", "project", "future", "will", "should", "would", "search" and similar terms or expressions. The forward-looking statements in this press release are based on management's current expectations, which are subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond the control of ReWalk. Significant factors that could materially differ between ReWalk's actual results and those reflected in the forward-looking statements include: ReWalk's ability to obtain capital from its equity and debt financings, taking into account limitations imposed by its Form S-3, the price range; its common shares and its position on the financial markets, as well as the risk that these financings dilute ReWalk's shareholders or limit its activities; ReWalk's ability to remain in compliance with Nasdaq's market-keeping requirements on the listing market and the risk that its common shares will be removed from the list if it can not do so; the risk of a decrease in liquidity on the ReWalk common stock market and a reduced market capitalization of the Company following the recent consolidation of the shares, as well as dilution risk following the recent increase in authorized capital; ReWalk's expectations for future growth, including its ability to increase sales in its existing geographic markets, expand into new markets and achieve planned spending reductions; conclusion of ReWalk's management and the opinion of ReWalk's auditors that there are serious doubts as to ReWalk's ability to continue as a going concern; ReWalk's ability to maintain and develop its reputation and acceptance of its products by the market; ReWalk's ability to obtain reimbursement of its products by third-party payers; ReWalk's limited operating history and ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations with respect to its clinical research program and clinical results; ReWalk's ability to improve its products and develop new products; ReWalk's ability to repay its secured debts; the outcome of ongoing class action lawsuits relating to ReWalk's initial public offering; ReWalk's compliance with medical device notification regulations to report adverse events related to its products and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to obtain and maintain regulatory approvals; ReWalk's expectations regarding the results of ReWalk's mandatory mandatory 522 mandatory post-marketing surveillance study and the potential regulatory and food regulatory developments at ReWalk's Regulatory and On-Demand 510K ReStore for patients with stroke; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid any infringement of the intellectual property rights of others; the risk of a cybersecurity attack or a breach of our computer systems significantly disrupting our business operations; ReWalk's ability to effectively utilize the proceeds of securities offerings; ReWalk's ability to establish a marketing channel for its products in China; the risk of substantial dilution resulting from the periodic issue of ReWalk common shares; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; the impact of ReWalk's common market price on the determination of whether ReWalk is a passive foreign investment company; market conditions; the satisfaction of customary closing conditions related to the offer; the expected closing date of the investment; the expected use of the net proceeds of the investment; and other factors described under "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year ended December 31, 2018, filed with the US Securities and Exchange Commission Furnished at the SEC. Any forward-looking statements made in this press release are only effective as of the date of publication. Factors or events that may cause ReWalk's actual results to differ from statements in this document may occur from time to time and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk assumes no obligation to publicly update forward-looking statements, whether as a result of new information, future developments or otherwise. unless the law requires it.

The story continues